recombinant mouse il-19 protein  (Bio-Techne corporation)

Journal: British Journal of Pharmacology

Article Title: Treatment with IL‐19 improves locomotor functional recovery after contusion trauma to the spinal cord

doi: 10.1111/bph.14193

Figure Lengend Snippet: Spinal cord trauma up‐regulated expression of IL‐19 and its receptor in spinal cord. Gene expression (A) of IL‐19, IL‐20R1 and IL‐20R2 was measured by quantitative real‐time PCR (n = 8). In (B), the results from Western blotting and the corresponding quantification (n = 3) for IL‐19, IL‐20R1 and IL‐20R2 were shown. Data shown are the means ± SD. *P < 0.05, significantly different from the sham‐operated mice.

Article Snippet: We used mouse recombinant IL‐19, supplied by R&D Inc (Minneapolis, MN), diluted in 0.0025% BSA in sterile PBS.

Techniques: Expressing, Real-time Polymerase Chain Reaction, Western Blot

Journal: British Journal of Pharmacology

Article Title: Treatment with IL‐19 improves locomotor functional recovery after contusion trauma to the spinal cord

doi: 10.1111/bph.14193

Figure Lengend Snippet: Mice were exposed to spinal cord trauma and treated i.p. with IL‐19 (5 and 10 ng·g−1 day−1) or vehicle (A). Mice were randomly divided into three groups as follows: (i) SCI mice treated with vehicle; (ii) SCI mice treated with IL‐19 (10 ng·g−1 ·day−1, i.p.); and (iii) SCI mice treated with IL‐19 (10 ng·g−1 ·day−1, i.p.) and IL‐19 blocking antibody (10 mg·kg−1·day−1, s.c.) (B). The time courses of locomotor recovery evaluated by the 9‐point BMS scoring after SCI are shown. Data shown are the means ± SD. n = 7 in each group; *P < 0.05, significantly different from the vehicle‐treated group; #P < 0.05, significantly different from the IL‐19‐treated group.

Article Snippet: We used mouse recombinant IL‐19, supplied by R&D Inc (Minneapolis, MN), diluted in 0.0025% BSA in sterile PBS.

Techniques: Blocking Assay

Journal: British Journal of Pharmacology

Article Title: Treatment with IL‐19 improves locomotor functional recovery after contusion trauma to the spinal cord

doi: 10.1111/bph.14193

Figure Lengend Snippet: Effects of treatment with IL‐19 (10 ng·g−1·day−1) and IL‐19 blocking antibody (10 mg·kg−1·day−1) on loss of motor neurons and microglial and glial activation in mice exposed to SCI. Sections (2 mm rostral to the epicentre, scale bar = 50 μm) were immuno‐stained with antibodies recognizing NeuN (A), activated glial (GFAP, B) and microglia (IBA1, C) and the corresponding quantification (D). The mRNA (E) and protein (F) expressions of NeuN, GFAP and IBA1 were determined by quantitative real‐time PCR and Western blotting respectively. Data shown are the means ± SD; n = 7 in each group. *P < 0.05, significantly different from the vehicle‐treated group; #P < 0.05, significantly different from the IL‐19‐treated group.

Article Snippet: We used mouse recombinant IL‐19, supplied by R&D Inc (Minneapolis, MN), diluted in 0.0025% BSA in sterile PBS.

Techniques: Blocking Assay, Activation Assay, Staining, Real-time Polymerase Chain Reaction, Western Blot

Journal: British Journal of Pharmacology

Article Title: Treatment with IL‐19 improves locomotor functional recovery after contusion trauma to the spinal cord

doi: 10.1111/bph.14193

Figure Lengend Snippet: Immune modulation of treatment with IL‐19 (10 ng·g−1·day−1) and IL‐19 blocking antibody (10 mg·kg−1·day−1) in mice with SCI. Representative micrographs (A) and corresponding quantification (B) of lumbar spinal cord sections (2 mm rostral to epicentre, scale bar = 50 μm) stained for immunofluorescence using antibody recognizing CD68 are shown. Graphs show the mRNA levels of CD68 (C) and protein levels of TNF‐α (D) and CCL2 (E) in spinal cord, mRNA levels of T‐bet (F) and GATA‐3 (G) in spleen, and mRNA levels of IFN‐γ (H), IL‐12 (I), inducible NOS (iNOS) (J), Arg1 (K), Ym1 (M) and CD206 (N) in spinal cord and spleen of mice. Data shown are the means ± SD; n = 7 in each group. *P < 0.05, significantly different from the vehicle‐treated group; #P < 0.05, significantly different from the IL‐19‐treated group.

Article Snippet: We used mouse recombinant IL‐19, supplied by R&D Inc (Minneapolis, MN), diluted in 0.0025% BSA in sterile PBS.

Techniques: Blocking Assay, Staining, Immunofluorescence

Journal: British Journal of Pharmacology

Article Title: Treatment with IL‐19 improves locomotor functional recovery after contusion trauma to the spinal cord

doi: 10.1111/bph.14193

Figure Lengend Snippet: Effects of treatment with IL‐19 (10 ng·g−1·day−1) and IL‐19 blocking antibody (10 mg·kg−1·day−1) on angiogenesis in spinal cord of mice exposed to SCI. Graphs show the mRNA levels (n = 7) of three isoforms of VEGF (A, VEGF120, VEGF164, and VEGF188) in the injured spinal cords. In (B), Western blotting results and the corresponding quantification (B, n = 3) of PECAM‐1 are shown. VEGF‐A protein levels (C, n = 7) in spinal cord were determined by elisa. Data shown are the means ± SD. *P < 0.05, significantly different from the vehicle‐treated group; #P < 0.05, significantly different from the IL‐19‐treated group.

Article Snippet: We used mouse recombinant IL‐19, supplied by R&D Inc (Minneapolis, MN), diluted in 0.0025% BSA in sterile PBS.

Techniques: Blocking Assay, Western Blot, Enzyme-linked Immunosorbent Assay

Journal: British Journal of Pharmacology

Article Title: Treatment with IL‐19 improves locomotor functional recovery after contusion trauma to the spinal cord

doi: 10.1111/bph.14193

Figure Lengend Snippet: Effects of treatment with IL‐19 (10 ng·g−1·day−1) and IL‐19 blocking antibody (10 mg·kg−1·day−1) on oxidative stress in spinal cord of mice exposed to SCI. In (A), Western blotting results and the corresponding quantification (n = 3) of HO‐1 are shown. Graphs show the mRNA levels (n = 7) of HO‐1 (B) and the levels of MDA (C ) in the injured spinal cords. Data shown are the means ± SD. *P < 0.05, significantly different from the vehicle‐treated group; #P < 0.05, significantly different from the IL‐19‐treated group.

Article Snippet: We used mouse recombinant IL‐19, supplied by R&D Inc (Minneapolis, MN), diluted in 0.0025% BSA in sterile PBS.

Techniques: Blocking Assay, Western Blot

Journal: British Journal of Pharmacology

Article Title: Treatment with IL‐19 improves locomotor functional recovery after contusion trauma to the spinal cord

doi: 10.1111/bph.14193

Figure Lengend Snippet: Effects of knockout of the IL‐19 gene on locomotor function in mice exposed to spinal cord trauma. The time courses of locomotor recovery evaluated by the 9‐point BMS scoring after SCI are shown. Data shown are the means ± SD; n = 6 in each group. *P < 0.05, significantly different from the wild‐type mice.

Article Snippet: We used mouse recombinant IL‐19, supplied by R&D Inc (Minneapolis, MN), diluted in 0.0025% BSA in sterile PBS.

Techniques: Knock-Out

Journal: British Journal of Pharmacology

Article Title: Treatment with IL‐19 improves locomotor functional recovery after contusion trauma to the spinal cord

doi: 10.1111/bph.14193

Figure Lengend Snippet: A diagram illustrating the effects of IL‐19 in secondary injuries and functional recovery after SCI.

Article Snippet: We used mouse recombinant IL‐19, supplied by R&D Inc (Minneapolis, MN), diluted in 0.0025% BSA in sterile PBS.

Techniques: Functional Assay